Aequus Pharmaceuticals (AEQ) Stock Statistics & Valuation Metrics
Total Valuation
Aequus Pharmaceuticals has a market cap or net worth of EUR 424.90K. The enterprise value is EUR 7.21M.
- Market Cap
- EUR 424.90K
- Enterprise Value
- EUR 7.21M
Share Statistics
Aequus Pharmaceuticals has 132,634,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 132,634,430
- Owned by Insiders
- 6.31%
- Owned by Institutions
- ―
Financial Efficiency
Aequus Pharmaceuticals’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is -753.79%.
- Return on Equity (ROE)
- 0.34
- Return on Assets (ROA)
- -2.72
- Return on Invested Capital (ROIC)
- -753.79%
- Return on Capital Employed (ROCE)
- 0.35
- Revenue Per Employee
- 48.69K
- Profits Per Employee
- -181.47K
- Employee Count
- 12
- Asset Turnover
- 0.73
- Inventory Turnover
- 6.66
Valuation Ratios
The current PE Ratio of Aequus Pharmaceuticals is 3.13. Aequus Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- 3.13
- PS Ratio
- 1.41
- PB Ratio
- -0.10
- Price to FCF
- -14.15
- Price to Operating Cash Flow
- -14.15
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Aequus Pharmaceuticals had revenue of 584.24K and earned -2.18M in profits. Earnings per share was -0.02.
- Revenue
- 584.24K
- Gross Profit
- 199.97K
- Operating Income
- -2.13M
- Pretax Income
- -2.18M
- Net Income
- -2.18M
- EBITDA
- -1.79M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -443.32K and capital expenditures -3, giving a free cash flow of -443.32K billion.
- Operating Cash Flow
- -443.32K
- Free Cash Flow
- -443.32K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Aequus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.07%
- Earnings Yield
- 31.15%
Stock Price Statistics
- Beta
- 0.91
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 10.00K
Important Dates
Aequus Pharmaceuticals upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Aequus Pharmaceuticals as a current ratio of 0.04, with Debt / Equity ratio of -102.44%
- Current Ratio
- 0.04
- Quick Ratio
- 0.04
- Debt to Market Cap
- 4.64
- Net Debt to EBITDA
- -3.66
- Interest Coverage Ratio
- -8.40
Taxes
In the past 12 months, Aequus Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aequus Pharmaceuticals EV to EBITDA ratio is 15.62, with an EV/FCF ratio of -142.48.
- EV to Sales
- 14.21
- EV to EBITDA
- 15.62
- EV to Free Cash Flow
- -142.48
- EV to Operating Cash Flow
- -142.48
Balance Sheet
Aequus Pharmaceuticals has EUR 35.08K in cash and marketable securities with EUR 6.64M in debt, giving a net cash position of -EUR 6.60M billion.
- Cash & Marketable Securities
- EUR 35.08K
- Total Debt
- EUR 6.64M
- Net Cash
- -EUR 6.60M
- Net Cash Per Share
- -EUR 0.05
- Tangible Book Value Per Share
- -EUR 0.05
Margins
Gross margin is 50.97%, with operating margin of -38.19%, and net profit margin of 43.95%.
- Gross Margin
- 50.97%
- Operating Margin
- -38.19%
- Pretax Margin
- 43.95%
- Net Profit Margin
- 43.95%
- EBITDA Margin
- 90.99%
- EBIT Margin
- 71.45%
